Results 41 to 50 of about 23,498 (195)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

Frontiers in Immunology, 2021
ObjectiveTo determine the transfer of the monoclonal antibody natalizumab into breastmilk and to evaluate drug and serum neurofilament light chain ((s)NfL) levels in natalizumab exposed pregnancies and lactation periods.MethodsEleven women with relapsing
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgün, Tjalf Ziemssen   +4 more
doaj   +1 more source

Silent progression in disease activity-free relapsing multiple sclerosis. [PDF]

, 2019
ObjectiveRates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pretreatment era.
Baranzini, Sergio E, Barba, Patrick, Bevan, Carolyn, Bischof, Antje, Bove, Riley, Caverzasi, Eduardo, Cree, Bruce AC, Gelfand, Jeffrey M, Gomez, Refujia, Goodin, Douglas S, Graves, Jennifer, Green, Ari J, Gundel, Tristan, Hauser, Stephen L, Henry, Roland G, Hollenbach, Jill A, Kirkish, Gina, Oksenberg, Jorge R, Papinutto, Nico, Ragan, Nicholas R, Romeo, Andrew, Rush, Gillian Q, Sacco, Simone, Santaniello, Adam, Stern, William A, University of California, San Francisco MS-EPIC Team, Wilson, Michael R, Zamvil, Scott S, Zhao, Chao, Zhu, Alyssa H   +29 more
core   +1 more source

Patient monitoring during treatment with natalizumab (ORP-24) [PDF]

Neurology Letters, 2023
Natalizumab (Tysabri), a recombinant humanized monoclonal antibody selective for α4- integrin, is indicated for CIS, RRMS, and active SPMS in adults.
Zohreh Abna
doaj  

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +9 more
wiley   +1 more source

Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study ‘TOPICS greece’

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021
Background Natalizumab is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS). Objective To assess the real-world long-term safety of natalizumab in RRMS.
Panagiotis Karanasios, Georgios Karachalios, Rania Gourgioti, Antonia Alexopoulou, Vasileios Mastorodemos,   +5 more
doaj   +1 more source

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

Frontiers in Immunology, 2023
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval ...
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado, Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho   +16 more
doaj   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]

, 2016
Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai, Liu, Yan-Qun, Xie, Chong, Zhang, Guang-Xian   +3 more
core   +2 more sources

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial [PDF]

, 2016
Introduction The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study.
Deb Steiner, Geoffrey Kuesters, J. T. Tibung, Jun-Ichi Kira, Nisha Lucas, Nobuhisa Ohtsuka, null null, Shinichi Torii, Shuji Kishida, Takahiko Saida, Takashi Yamamura, Yan Ling   +11 more
core   +1 more source